Craft

Burning Rock Biotech

Stock Price

$2.8

2024-10-29

Market Capitalization

$28.6 M

2024-10-29

Revenue

¥539.6 M

FY, 2025

Burning Rock Biotech Summary

Company Summary

Overview
Burning Rock Biotech (燃石医学) is a company that specializes in next-generation sequencing (NGS) diagnostics solutions for precision medicine in oncology. Its business consists of NGS-based therapy selection testing for late-stage cancer patients; pharmaceutical services on biomarker detection and companion diagnostics developing; and NGS-based cancer early detection. The company provides OncoScreen, a cancer mutation profiling tissue kit; OncoCompass, a liquid biopsy test for cancer patients; brPROPHET, a residual disease detection and monitoring tool; OverC, in vitro diagnostic device for the detection of DNA methylation marker; etc.
Type
Public
Status
Active
Founded
2014
HQ
Guang Zhou, CN | view all locations
Website
https://www.brbiotech.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

Operating MetricsView all

Contracted Partner Hospitals

49
19.5%

FY, 2022

Patients

27.4K
3.0%

FY, 2022

Physicians Served

949
14.1%

FY, 2022

LocationsView all

4 locations detected

  • Guang Zhou, Guang Dong Sheng HQ

    China

    398H+R42 Guangzhou International Biological Island Shandi Park, 番禺区 Guang Zhou Shi

  • Irvine, CA

    United States

    121 Innovation Dr

  • Beijing, Bei Jing Shi

    China

    Room 912, Unit 3, Phase 1, SOHO, Guanghua Road

  • Shanghai, Shang Hai Shi

    China

    Block C, Floor 6, Building 10, Pujiang Wisdom Plaza, No. 2168 Chenhang Road

Burning Rock Biotech Financials

Summary Financials

Revenue (FY, 2025)
¥539.6M
Gross profit (FY, 2025)
¥424.7M
Net income (FY, 2025)
(¥55.3M)
Cash (FY, 2025)
¥478.4M
EBIT (FY, 2025)
(¥55.1M)
Enterprise value
($415.5M)

Footer menu